Pharmacokinetics, Dynamics and Metabolism, Translational Medicine & Early Development, Sanofi, 3 Digue d'Alfortville, 94140, Alfortville, France; INSERM UMR-S 1144, UFR de Pharmacie, Faculté de Santé, Université de Paris, 4 avenue de l'Observatoire, 75006, Paris, France.
Rare and Neurologic Diseases Research Therapeutic Area, Sanofi, 1 Avenue Pierre Brossolette, 91380, Chilly-Mazarin, France.
Neuropharmacology. 2021 Jun 15;191:108588. doi: 10.1016/j.neuropharm.2021.108588. Epub 2021 Apr 30.
The inducible p25 overexpression mouse model recapitulate many hallmark features of Alzheimer's disase including progressive neuronal loss, elevated Aβ, tau pathology, cognitive dysfunction, and impaired synaptic plasticity. We chose p25 mice to evaluate the physical and functional integrity of the blood-brain barrier (BBB) in a context of Tau pathology (pTau) and severe neurodegeneration, at an early (3 weeks ON) and a late (6 weeks ON) stage of the pathology. Using in situ brain perfusion and confocal imaging, we found that the brain vascular surface area and the physical integrity of the BBB were unaltered in p25 mice. However, there was a significant 14% decrease in cerebrovascular volume in 6 weeks ON mice, possibly explained by a significant 27% increase of collagen IV in the basement membrane of brain capillaries. The function of the BBB transporters GLUT1 and LAT1 was evaluated by measuring brain uptake of d-glucose and phenylalanine, respectively. In 6 weeks ON p25 mice, d-glucose brain uptake was significantly reduced by about 17% compared with WT, without any change in the levels of GLUT1 protein or mRNA in brain capillaries. The brain uptake of phenylalanine was not significantly reduced in p25 mice compared with WT. Lack of BBB integrity, impaired BBB d-glucose transport have been observed in several mouse models of AD. In contrast, reduced cerebrovascular volume and an increased basement membrane thickness may be more specifically associated with pTau in mouse models of neurodegeneration.
可诱导的 p25 过表达小鼠模型重现了阿尔茨海默病的许多标志性特征,包括进行性神经元丧失、Aβ 升高、tau 病理学、认知功能障碍和突触可塑性受损。我们选择 p25 小鼠来评估 Tau 病理学(pTau)和严重神经退行性变背景下血脑屏障(BBB)的物理和功能完整性,分别在病理学的早期(3 周 ON)和晚期(6 周 ON)阶段进行评估。使用原位脑灌注和共聚焦成像,我们发现 p25 小鼠的脑血管表面积和 BBB 的物理完整性没有改变。然而,在 6 周 ON 小鼠中,脑血管体积显著减少了 14%,这可能是由于脑毛细血管基底膜中的胶原 IV 显著增加了 27%所致。通过测量 d-葡萄糖和苯丙氨酸的脑摄取,评估了 BBB 转运蛋白 GLUT1 和 LAT1 的功能。在 6 周 ON 的 p25 小鼠中,与 WT 相比,d-葡萄糖脑摄取显著减少了约 17%,而脑毛细血管中 GLUT1 蛋白或 mRNA 水平没有任何变化。与 WT 相比,p25 小鼠的苯丙氨酸脑摄取没有明显减少。在几种 AD 小鼠模型中观察到 BBB 完整性缺失和 BBB 葡萄糖转运受损。相比之下,脑血管体积减少和基底膜厚度增加可能与神经退行性变小鼠模型中的 pTau 更相关。